Efficacy comparison between sitagliptin and pioglitazone in the treatment of the obesity type 2 diabetes mellitus patients unresponsive to treatment with metformin

Objective:To compare the effects and safety between sitagliptin and pioglitazone in the treatment of the obesity type 2 diabetes mellitus patients unresponsive to treatment with metformin.Methods:Ninety-eight obesity type 2 diabetes mellitus patients unresponsive to treatment with metformin were divided into the group A and group B according to random number table method(49 cases each group).The group A and group B were additionally treated with sitagliptin and pioglitazone,respectively.The levels of blood glucose,insulin,body mass index(BMI),blood lipid and insulin resistance index,and adverse reactions between two groups were compared.Results:Before treatment,the differences of the levels of blood glucose,insulin,BMI,blood lipid and insulin resistance between two groups were not statistically significant(P>0.05),and all indexes in two groups were significantly improved after treatment.After treatment,the differences of the levels of fasting blood glucose,insulin and blood lipid between two groups were not statistically significant(P>0.05),and the levels of postprandial 2 h blood glucose and BMI in group A were significantly lower than those in group B(P<0.05).The incidence rates of adverse reactions in group A and group B were 10.20% and 14.29%,respectively,the difference of which was not statistically significant(P>0.05),and there were not severe adverse reactions in two groups.Conclusions:The effects of obesity type 2 diabetes mellitus treated with metformin combined with sitagliptin or pioglitazone are ideal and safe,but the effects of sitagliptin on postprandial blood glucose and body weight control are better than those of pioglitazone.